Publication Year

Doepker C, Movva N, Cohen SS, Wikoff DS. 2022. Benefit-risk of coffee consumption and all-cause mortality: A systematic review and disability adjusted life year analysis. Food Chem Toxicol 170:113472, doi: 10.1016/j.fct.2022.113472.

Boles C, Zisook R, Buerger AN, Hamaji C, Mathis C, Lauer D, et al. 2022. Semi-quantitative microbial risk assessment: a narrative review and proposed framework for health and safety practitioners. Journal of Public Health and Emergency 6:34.

Bisesi JH, Buerger AN, Parente C, Martyniuk CJ. Effects of endocrine disrupting compounds on host microbiome dynamics: Implications for gastrointestinal physiology and health. Presented at American Geophysical Union Fall Meeting, Chicago, IL, 2022.

Broome CM, Hooda N, Su J, Jiang X, Nicholson G, Frankenfeld CL, Iglesias-Rodriguez M, Fryzek J, Patel Parija. 2022. Medically-attended anxiety and depression is increased among newly diagnosed patients with cold agglutinin disease: Analysis of an integrated claim-clinical cohort in the United States. PLOS ONE open access, https://doi.org/10.1371/journal.pone.0276617.

Perry C, Proctor D. Short-term environmental inhalation toxicity criteria for airborne manganese protective of neurological and respiratory effects for use in air toxics risk assessment. Presentation 5-15.T-04 to Society of Environmental Toxicology and Chemistry, Pittsburgh PA, November 2022.

Proctor D, Mittal L, Vivanco S, Perry C, Blanchette A. Probabilistic health risk assessment for residential exposures to metals in electric arc furnace (EAF) steel slag. Presentation 5.15.P-Th123 to Society of Environmental Toxicology and Chemistry, Pittsburgh PA, November 2022.

Estorninos EM, Cohen S, Reichert R, Lebumfacil J, Jankovic I, Chen Y, Egli D.  Real-world effectiveness of young child formula containing Limosilactobacillus reuteri on gastrointestinal tolerance and related behaviors in toddlers: a cross-sectional observational study.  To be presented at Excellence In Pediatrics (EIP), December 2022, Amsterdam, Netherlands

Gillezeau C, Movva N, van Gerwen M, Rabon-Stith K, Shire N, Brohawn PZ, Taioli E, Fryzek J. 2022. Interferon gamma expression and mortality in unselected cohorts of urothelial bladder cancer patients. PLoS One 17(8):e0271339, doi: 10.1371/journal.pone.0271339. PMID: 36040901; PMCID: PMC9426882.

Cohen SS, Bylsma LC, Movva N, Alexander DD. 2022. Theoretical attributable risk analysis and Disability Adjusted Life Years (DALYs) based on increased dairy consumption. BMC Public Health 22(1):1625, doi: 10.1186/s12889-022-14042-7.

Heintz MM, Chappell GA, Thompson CM, Haws LC. 2022. Evaluation of transcriptomic responses in livers of mice exposed to the short-chain PFAS compound HFPO-DA. Front Toxicol 4:937168, https://doi.org/10.3389/ftox.2022.937168.

Goyak KO, Sarang SS, Franzen A, Borghoff SJ, Ryman-Rasumssen JP. 2022. Adverse outcome pathway (AOP): α2u-globulin nephropathy and kidney tumors in male rats. Crit Rev Toxicol, online open access.

Henderson RG, Franke KS, Payne LE, Franzen A. 2022. Cannabidiol safety data: A systematic mapping study. Cannabis Cannabinoid Res (epub ahead of print), doi: 10.1089/can.2022.0100, PMID: 36251454.

Henderson RG, Nguyen H. 2022. Pathways to the US supplement market: New Dietary Ingredient notification and Generally Recognized as Safe determination. Chapter 19 in: Ruthsatz M, Wong AW (eds), Nutrition, Health, and Disease: Regulatory Policy Matters. Regulatory Affairs Professionals Society (RAPS), online store.

Knotts T, Diokno R, Husfeld C, Weinberger D, Mease K, Wollowitz S, Kramer S, Donovan J. Vocacapsaicin (formerly CA-008): A water-soluble prodrug for rapid release of capsaicin for the treatment of postsurgical pain. Presentation to American Association of Pharmaceutical Scientists, AAPS PHARMSCI 360, Boston, MA, October 2022.

Suh M, Cloud M, Balasubramanian A, Movva N, Fryzek J, Cohen S. 2022. A systematic literature review (SLR) of MTAP deletions in multiple solid and hematologic cancers. PROSPERO 2022 CRD42022354037.

Danese MD, Schenfeld J, Shaw J, Gawade P, Balasubramanian A, Kelsh M, et al. 2022. Association between granulocyte colony-stimulating factor (G-CSF) use and myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) among elderly patients with breast, lung, or prostate cancer.  Adv Ther 39(6):2778–2795. doi:10.1007/s12325-022-02141-1.

Schenfeld J, Gong T, Henry D, Kelsh M, Gawade P, Peng Y, Bradbury BD, Li S. 2022. Patterns of primary prophylactic granulocyte colony-stimulating factor use in older Medicare patients with cancer receiving myelosuppressive chemotherapy. Support Care Cancer 30(7):6327–6338. doi: 10.1007/s00520-022-06967-x.

Hulsey A, Cekola P, Henrikson A, Reichert H, Cohen SS, Torres KA. 2022. Growth and tolerance with an amino acid based enteral formula: A two-year retrospective study from a children’s rehabilitation hospital. J Clin Nutr Dietet 8(8):181.